Intrathecal Infusion in Cancer Pain Surgery

Area of Science:

• Oncology
• Pain Management
• Neurosurgery

Background:

• Cancer pain significantly impacts quality of life in advanced malignancy.
• Systemic therapies often lead to refractory pain or side effects.
• Intrathecal drug delivery (ITDD) provides targeted analgesia with reduced systemic toxicity.

Purpose of the Study:

• To review the mechanisms of cancer pain and the rationale for intrathecal therapy.
• To discuss pharmacological agents, patient selection, and technical aspects of ITDD.
• To highlight the benefits and potential complications of ITDD for refractory cancer pain.

Main Methods:

• Exploration of physiological mechanisms of cancer pain.
• Review of pharmacological profiles of intrathecal agents.
• Discussion of patient selection, timing, and technical implantation aspects of ITDD.

Main Results:

• ITDD significantly improves pain control and quality of life in cancer patients.
• Early integration of ITDD may offer superior symptom management compared to late-stage use.
• Careful patient selection, individualized regimens, and precise technique are key to optimal outcomes.

Conclusions:

• Intrathecal drug delivery is an effective treatment for refractory cancer pain.
• Optimizing outcomes requires careful planning, multidisciplinary follow-up, and consideration of potential complications.
• Further research is needed to refine drug combinations, device technology, and early intervention strategies.